Credit Suisse’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Credit Suisse’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$2	–	3901
2022 Q4	$2	Sell	2 -235	-99%	-$335	﹤0.01%	3910
2022 Q3	$1K	Buy	237 +198	+508%	+$701	﹤0.01%	3991
2022 Q2	$0	Buy	+39	New	+$190	﹤0.01%	4530
2021 Q4	–	Sell	-165,863	Closed	-$1.23M	–	4723
2021 Q3	$1.23M	Sell	165,863 -384,699	-70%	-$2.38M	﹤0.01%	3170
2021 Q2	$3.74M	Buy	550,562 +45,979	+9%	+$382K	﹤0.01%	2331
2021 Q1	$5.18M	Buy	+504,583	New	+$5.53M	﹤0.01%	2040
2018 Q3	–	Sell	-11,867	Closed	-$91K	–	4055
2018 Q2	$91K	Sell	11,867 -2,450	-17%	-$35.3K	﹤0.01%	3843
2018 Q1	$321K	Buy	+14,317	New	+$318K	﹤0.01%	3546
2017 Q4	–	Sell	-10,656	Closed	-$166K	–	4255
2017 Q3	$166K	Buy	+10,656	New	+$151K	﹤0.01%	3983

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Credit Suisse's JNCE Position: Q1 2023 in Review

Credit Suisse sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 2 shares — an estimated $2 sold.

Credit Suisse first reported a position in JNCE in Q3 2017 and held it in 9 quarters. The position peaked at $5.18M in Q1 2021. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

Credit Suisse reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 2 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $2.
Credit Suisse first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
Credit Suisse's Jounce Therapeutics, Inc. Common Stock position peaked at $5.18M in Q1 2021.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.